Occudo Quantitative Strategies LP Takes Position in Inari Medical, Inc. (NASDAQ:NARI)

Occudo Quantitative Strategies LP bought a new stake in shares of Inari Medical, Inc. (NASDAQ:NARI) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,289 shares of the company’s stock, valued at approximately $270,000.

A number of other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Inari Medical by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock valued at $287,354,000 after acquiring an additional 30,702 shares during the period. Jennison Associates LLC grew its position in shares of Inari Medical by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock valued at $90,014,000 after acquiring an additional 186,617 shares during the period. Bamco Inc. NY grew its position in shares of Inari Medical by 30.5% during the 4th quarter. Bamco Inc. NY now owns 1,312,528 shares of the company’s stock valued at $67,005,000 after acquiring an additional 306,399 shares during the period. American Century Companies Inc. grew its position in shares of Inari Medical by 9.1% during the 4th quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after acquiring an additional 89,108 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its position in shares of Inari Medical by 13.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 870,633 shares of the company’s stock valued at $44,446,000 after acquiring an additional 102,111 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Price Performance

NASDAQ:NARI opened at $79.97 on Friday. Inari Medical, Inc. has a 52 week low of $39.76 and a 52 week high of $79.99. The stock has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. The stock’s 50-day moving average price is $79.97 and its 200-day moving average price is $70.55.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.